Adaptive changes of serotonin 5-HT(2A) receptors in mice lacking the serotonin transporter

Neuroscience Letters

Volumn 262, Issue 2, 1999, Pages 113-116

  Rioux, Agnès ^a   Fabre, Véronique ^a   Peter Lesch, K ^b   Moessner, Rainald ^b   Murphy, Dennis L ^c   Lanfumey, Laurence ^a   Hamon, Michel ^a   Martres, Marie Pascale ^a  

^a INSERM   (France)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT(2A) receptor; Cerebral cortex; Down regulation; Knock out mice; Serotonin transporter; Striosomes

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIDEPRESSANT AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN MEMBRANE; CLAUSTRUM; CONTROLLED STUDY; CORPUS STRIATUM; KNOCKOUT MOUSE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SEROTONINERGIC TRANSMISSION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BINDING SITES; CARRIER PROTEINS; CELL MEMBRANE; CEREBRAL CORTEX; DOWN-REGULATION; FLUOROBENZENES; HETEROZYGOTE; HOMOZYGOTE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; NERVE TISSUE PROTEINS; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0033525562     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00049-X     Document Type: Article

References (21)

1. + and paroxetine on extracellular serotonin concentrations in serotonin transporter knock-out mice, Soc. Neurosci., 24 (1998) 1112 (440.2).
2. Bengel D., Heils A., Petri S., Seemann M., Glatz K., Andrews A., Murphy D.L., Lesch K.P. Gene structure and 5′-flanking regulatory region of the murine serotonin transporter. Mol. Brain Res. 44:1997;286-292.
3. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mössner R., Westphal H., Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('ecstasy') in serotonin transporter-deficient mice. Mol. Pharmacol. 53:1998;649-655.
4. Gerfen C.R., Baimbridge K.G., Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. USA. 82:1985;8780-8784.
5. Grahame-Smith D.G. Serotonin in affective disorders. Int. Clin. Psychopharmacol. 6:1992;5-13.
6. Green A.R., Cross A., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology. 119:1995;247-260.
7. 2 sites in cortex and amygdala. Brain Res. 614:1993;37-44.
8. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9:1994;19-26.
9. 1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J. Pharmacol. Exp. Ther. 268:1994;1432-1443.
10. 3H]MDL 100,907. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;446-454.
11. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
12. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43:1991;587-604.
13. 2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Biochem. Pharmacol. 42:1991;1099-1105.
14. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci. 1:1998;132-137.
15. 2 receptor transmembrane signaling system. Psychopharmacology. 99:1989;64-69.
16. 2A receptor induces an antidepressant-like effect in mice. Mol. Pharmacol. 52:1997;1056-1063.
17. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Revay R., Lesch K.P., Murphy D.L., Uhl G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA. 95:1998;7699-7704.
18. Toth M., Shenk T. Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription. Mol. Pharmacol. 45:1994;1095-1100.
19. Waeber C., Palacios J.M. Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia. Mol. Brain Res. 24:1994;199-209.
20. Wichems, C.H., Andrews, A.M., Heils, A., Li, O., Lesch, K.P. and Murphy, D.L., Spontaneous behavior differences and altered responses to psychomotor stimulants in mice lacking the serotonin transporter, Soc. Neurosci., 24 (1998) 1112 (440.1).
21. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.